Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
Akari Therapeutics Plc - American Depositary Shares (AKTX)
US:NASDAQ Investor Relations:
investor.akaritx.com/investor-relations
Company Research
Source: GlobeNewswire
Opened three clinical trials in 2018Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial for PNH patients resistant to treatment with Soliris where a patient is now being treatedPhase II trial in atypical haemolytic syndrome (aHUS) which opened Q4 2017 Trials focused on a separate group of diseases mediated by both the complement and leukotriene pathways Phase II trial in bullous pemphigoid (BP), recently opened with data expected Q1 2019Phase I/II trial in atopic keratoconjunctivitis (AKC) expected to commence Q3 2018, with data anticipated Q1 2019 NEW YORK and LONDON, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced its fina
Show less
Read more
Impact Snapshot
Event Time:
AKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKTX alerts
High impacting Akari Therapeutics Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AKTX
News
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 [Yahoo! Finance]Yahoo! Finance
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024GlobeNewswire
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
AKTX
Sec Filings
- 4/11/24 - Form 8-K
- 4/1/24 - Form 8-K
- 3/29/24 - Form 10-K
- AKTX's page on the SEC website